Venlafaxine, sertraline and escitalopram – 3 medicines that we know very well, in a slightly different way Case report
Article Sidebar
Published:
Jun 30, 2017
Keywords:
venlafaxine, sertraline, escitalopram, anxiety, panic disorder, obsessive-compulsive disorder
Main Article Content
Abstract
In the psychiatric treatment there should be considerate not only the substance but also its dose and patients history of treatment. In this paper we presented 3 cases in which the consideration of these factors significantly influenced the effectiveness of therapy.
Article Details
How to Cite
Polikowska , M. (2017). Venlafaxine, sertraline and escitalopram – 3 medicines that we know very well, in a slightly different way. Medycyna Faktow (J EBM), 10(2(35), 152-157. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2157
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wciórka J., Pużyński S., Rybakowski J.: Psychiatria. T. 2. Elsevier Urban & Partner, Wrocław 2012.
2. Thase M.E., Shelton R.C., Khan A.: Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J. Clin. Psychopharmacol. 2006; 26: 250-258.
3. Kennedy S.H., Gorwood P.: Successful management of major depressive disorder. Future Medicine Ltd, London 2014: 37.
4. Bazire S.: Przewodnik leków psychotropowych. Via Medica, Gdańsk 2014: 249.
5. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10: 51-61.
6. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259: 172-185.
7. Anderson I.M.: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 19-36.
8. Thase M.: Treatment of anxiety disorders with venlafaxine XR. Expert Rev. Neurother. 2006; 6(3): 269-282.
9. Montoya A., Bruins R., Katzman M., Blier P.: The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr. Dis. Treat. 2016; 12: 541-557.
10. Zullino D., Chatton A., Fresard E. et al.: Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes. Psychiatr. Q. 2015; 86(1): 69-82.
11. Thase M.E., Entsuah A.R., Rudolph R.L.: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241.
12. Soomro G.M.: Obsessive compulsive disorder. BMJ Clin. Evid. 2012; 2012.
13. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
14. Łoza B.: 30 lat SSRI: starsze i nowsze leki z grupy SSRI. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 214-219.
15. Skapinakis P., Caldwell D., Hollingworth W. et al.: A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol. Assess. 2016; 20(43): 1-392.
16. Skarphedinsson G., Weidle B., Ivarsson T.: Sertraline Treatment of Nonresponders to Extended Cognitive-Behavior Therapy in Pediatric Obsessive- Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2015; 25(7): 574-579.
17. Choi Y.J.: Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J. Am. Acad. Nurse Pract. 2009; 21(4): 207-213.
18. WHO: Depression. Fact sheets. Aktualizacja: luty 2017.
19. Goodwin R.D., Gorman J.M.: Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry 2002; 159: 1935-1937.
20. Wittchen H.U., Essau C.A.: Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J. Clin. Psychiatry 1993; 54(supl.): 9-15.
21. Rzewuska M.: Leczenie zaburzeń nerwicowych. W: Rzewuska M. (red.): Leczenie zaburzeń psychicznych. PZWL, Warszawa 2003: 100-139.
22. Stahl S.M., Gergel I., Li D.: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2003; 64: 1322-1327.
23. Davidson J., Bose A., Su G.: Escitalopram in the treatment of generalized anxiety disorder. [poster] 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologium; 2002 Jun 23–27, Montreal, Canada.
24. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 5-14.
2. Thase M.E., Shelton R.C., Khan A.: Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J. Clin. Psychopharmacol. 2006; 26: 250-258.
3. Kennedy S.H., Gorwood P.: Successful management of major depressive disorder. Future Medicine Ltd, London 2014: 37.
4. Bazire S.: Przewodnik leków psychotropowych. Via Medica, Gdańsk 2014: 249.
5. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10: 51-61.
6. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259: 172-185.
7. Anderson I.M.: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 19-36.
8. Thase M.: Treatment of anxiety disorders with venlafaxine XR. Expert Rev. Neurother. 2006; 6(3): 269-282.
9. Montoya A., Bruins R., Katzman M., Blier P.: The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr. Dis. Treat. 2016; 12: 541-557.
10. Zullino D., Chatton A., Fresard E. et al.: Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes. Psychiatr. Q. 2015; 86(1): 69-82.
11. Thase M.E., Entsuah A.R., Rudolph R.L.: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241.
12. Soomro G.M.: Obsessive compulsive disorder. BMJ Clin. Evid. 2012; 2012.
13. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
14. Łoza B.: 30 lat SSRI: starsze i nowsze leki z grupy SSRI. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 214-219.
15. Skapinakis P., Caldwell D., Hollingworth W. et al.: A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol. Assess. 2016; 20(43): 1-392.
16. Skarphedinsson G., Weidle B., Ivarsson T.: Sertraline Treatment of Nonresponders to Extended Cognitive-Behavior Therapy in Pediatric Obsessive- Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2015; 25(7): 574-579.
17. Choi Y.J.: Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J. Am. Acad. Nurse Pract. 2009; 21(4): 207-213.
18. WHO: Depression. Fact sheets. Aktualizacja: luty 2017.
19. Goodwin R.D., Gorman J.M.: Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry 2002; 159: 1935-1937.
20. Wittchen H.U., Essau C.A.: Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J. Clin. Psychiatry 1993; 54(supl.): 9-15.
21. Rzewuska M.: Leczenie zaburzeń nerwicowych. W: Rzewuska M. (red.): Leczenie zaburzeń psychicznych. PZWL, Warszawa 2003: 100-139.
22. Stahl S.M., Gergel I., Li D.: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2003; 64: 1322-1327.
23. Davidson J., Bose A., Su G.: Escitalopram in the treatment of generalized anxiety disorder. [poster] 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologium; 2002 Jun 23–27, Montreal, Canada.
24. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 5-14.